In an adult patient with acute or chronic mucopurulent sinusitis and no contraindications, should N‑acetylcysteine (NAC) be used and what is the appropriate dosage?

N-Acetylcysteine (NAC) for Sinusitis

N-acetylcysteine should NOT be routinely used for acute or chronic mucopurulent sinusitis in adults, as current high-quality evidence does not support its efficacy for this indication.

Guideline-Based Recommendations

The most recent 2025 American Academy of Otolaryngology guidelines for adult sinusitis 1 do not recommend NAC as part of standard treatment for either acute or chronic rhinosinusitis. The guidelines emphasize that:

• First-line treatment for chronic rhinosinusitis (CRS) consists of nasal saline irrigation and intranasal corticosteroid spray 1
• Antibiotics should NOT be routinely prescribed for CRS without acute exacerbation 1
• For viral rhinosinusitis, mucolytics are mentioned as potential palliative agents, but NAC is not specifically endorsed 1

Evidence Quality Assessment

Against NAC Use:

The highest quality evidence argues against NAC in sinusitis. A 2017 double-blind, placebo-controlled trial 2 in 39 patients with subacute sinusitis found that adding oral NAC (600 mg daily for 10 days) to standard antibiotic therapy provided no benefit in CT scan findings (Lund-Mackay scores) or symptom improvement compared to placebo.

Limited Supporting Evidence:

• A 2020 open-label study 3 in polypous rhinosinusitis showed some benefit with NAC 600 mg daily for 6 months post-surgery, but this was not placebo-controlled and involved a specific surgical population
• A 2024 preliminary trial 4 showed modest short-term benefits for NAC irrigation (not oral) after endoscopic sinus surgery, but only in the immediate 2-week postoperative period

Context from Other Conditions:

While NAC shows efficacy in other respiratory conditions like bronchiectasis 5 and has a favorable safety profile at doses up to 3000 mg/day 6, this does not translate to sinusitis treatment.

Clinical Algorithm

For acute mucopurulent sinusitis:

1. Determine if bacterial (symptoms >10 days, worsening after initial improvement, or severe symptoms with fever >39°C and purulent discharge for 3-4 consecutive days)
2. If bacterial: Consider antibiotics only if meeting these criteria
3. Do NOT add NAC - no evidence of benefit
4. Use symptomatic relief: saline irrigation, intranasal corticosteroids, analgesics

For chronic rhinosinusitis:

1. Confirm diagnosis with symptoms >12 weeks plus objective findings
2. Initiate nasal saline irrigation + intranasal corticosteroids 1
3. Do NOT routinely add NAC - insufficient evidence
4. Reserve antibiotics only for acute exacerbations with purulent discharge 1

FDA-Approved Indications

NAC is FDA-approved for mucolytic therapy via nebulization or direct instillation in respiratory conditions and for acetaminophen overdose 7. It is NOT approved for oral use in sinusitis.

Key Caveats

• The 1997 study 8 showing NAC failure was in immunodeficient patients, but this reinforces lack of efficacy even in high-risk populations
• Post-surgical NAC irrigation 4 may have limited utility in the immediate postoperative period, but this is distinct from treating active sinusitis
• Avoid the pitfall of prescribing NAC based on its theoretical mucolytic properties - clinical trial evidence does not support this practice in sinusitis

Safety Profile

If NAC were to be considered off-label despite lack of efficacy evidence, it has a favorable safety profile with primarily gastrointestinal side effects at doses up to 1200 mg/day 6, 5. However, safety does not justify use when efficacy is absent.